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whichwas the case in our patient. Of the reported cases, almost one
third of the patients continued to receive the drug after an initial
allergic reaction to ceftriaxone as they were diagnosed retro-
spectively.
In conclusion, ceftriaxone can cause fatal hemolysis and should
be used with caution especially in patients who are immunocom-
promised or have an underlying hematological condition. ARFmay
be the presenting manifestation of ceftriaxone-induced IHA and the
prognosis may be favorable for recovery with early diagnosis and
initiation of supportive therapy including dialysis.
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Large Granular Lymphocyte Leukemia (LGL) in a Child With
Hyper IgM Syndrome and Autoimmune Hemolytic Anemia
Brenda J. Kitchen, MD* and Laurence A. Boxer, MD
INTRODUCTION
Large granular lymphocyte leukemia (LGL) is a rare, indolent
form of non-Hodgkin’s lymphoma. This clonal lymphoproliferative
disease arises most frequently fromT-cells and less commonly from
natural killer (NK) cells [1]. The median age at presentation is 60
years old with less than 10% of patients younger than 40 years of
We describe a female with a history of autosomal recessive
hyper-IgM (HIGM) syndrome along with a history of autoimmune
hemolytic anemia and intermittent lymphadenopathy. She subse-
quently developed neutropenia, lymphocyostosis and mild throm-
bocytopenia. Flow cytometry of the peripheral blood revealed the
presence of a marked predominance of cytotoxic T lymphocytes,
shown to be clonal, with concomitant natural killer (NK) antigen
expression. She responded to weekly methotrexate therapy. Pediatr
Blood Cancer 2008;50:142–145.  2006 Wiley-Liss, Inc.
Key words: autoimmune hemolytic anemia; granular lymphocyte leukemia; hyper-IgM syndrome
——————
Division of Hematology/Oncology, Department of Pediatrics and
Communicable Diseases, University of Michigan, Mott Children’s
Hospital, Ann Arbor, Michigan
*Correspondence to: Brenda J. Kitchen, Women’s Hospital Rm L2110,
1500 E. Medical Center Dr., Box 0238, Ann Arbor, MI 48109.
E-mail: nkbrenda@umich.edu.
Received 5 January 2006; Accepted 18 April 2006
 2006 Wiley-Liss, Inc.
DOI 10.1002/pbc.20902
142 Brief Reports
age. LGL is quite rare in children [2]. While a third of patients are
asymptomatic at presentation, when present, symptoms are often
related to infections secondary to neutropenia [3]. Several condi-
tions have been associated with LGL, most commonly rheumatoid
arthritis (RA) in approximately 25–30% of patients and anemia in
up to 20% of patients including pure red cell aplasia and hemolytic
anemia [4].
CASE REPORT
Our patient, an only child, first presented at 16 months of age
with gastroenteritis and splenomegaly. At 23 months of age she
developed hepatosplenomegaly and a compensated Coombs posi-
tive autoimmune hemolytic anemia. Her evaluation revealed a high
IgM titer to CMV. Her serum IgMwasmildly elevated at 177 mg/dl
(NL range 48–168) with an IgG of 20 (NL range 553–971) and
IgA< 7. The patient was maintained on monthly immunoglobulin
infusions without significant infectious complications. It was felt
that she had an autosomal recessive form of a hyper-IgM (HIGM)
syndrome. At 6 years of age she developed diffuse lymphadenop-
athy. A lymph node biopsy revealed an atypical lymphoid hyper-
plasia. She was then treated with 6-mercaptopurine with near
complete regression of the lymphadenopathy, but persistent hepato-
splenomegaly. Her IgM level was 1750 at that time. She had a
waxing and waning autoimmune hemolytic anemia over the next 4
years with relapses when attempts were made to taper off
prednisone. Cyclosporine was later added in an effort to taper off
steroids with limited success. She alsowas treated on two occasions
with Rituximab with only transient success. At age 13 she under-
went for splenectomy for this refractory hemolytic anemia and
neutropenia. Her anemia and neutropenia remitted after the surgery.
Two months later she developed massive ascites of uncertain
etiology. Over the course of several months she required multiple
paracentesis procedures. Further genetic studies revealed her to
have activation-induced cytidine deaminase deficiency.
She next presented with a cough, muscle weakness and weight
loss. ACBC at that time revealed aWBC81,000/mm3, Hgb 9.2 g/dl,
platelets 245,000/mm3. The peripheral blood smear revealed
numerous large, granular lymphocytes along with neutropenia.
Flow cytometry on the peripheral blood was consistent with large
granular lymphocytic leukemia with the presence of cytotoxic
lymphocytes (Table I). T-cell gene rearrangement studies by PCR
detected a clonal rearrangement of the TCR g (gamma) gene. Since
her presentationwith T-LGL 1 year ago, she has beenmaintained on
weekly methotrexate (Table II). Her hepatomegaly has subse-
quently resolved along with resolution of her cytopenias and
positive Coombs’ test.
DISCUSSION
Approximately 10–15% of peripheral blood mononuclear cells
are large granular lymphocytes, the majority of which are NK cells
(CD3 CD8þ). In 1977 McKenna first reported a syndrome with
neutropenia and increased numbers of granular lymphocytes and in
1985 Loughran proposed the term LGL leukemia based on tissue
invasion of the bone marrow, spleen and liver [5,6]. The FAB
recognized LGL as a subgroup of chronic T-cell leukemia in 1989
and by 1993 Loughran proposed further sub classification into
T-LGL and NK-LGL leukemia [7]. In 1994 the International
Lymphoma Study Group proposed a Revised European-American
Classification of Lymphoid Neoplasms [8]. T-Cell LGL is an
indolent form of non-Hodgkin’s lymphoma characterized by a
clonal lymphoproliferation. NK-cell LGL are germline and usually
not clonal in nature. LGLmost commonly is due to the proliferation
of cytotoxic T-cells (85%) and less commonly to NK cells (15%).
Even though T-LGL is the most common T-cell neoplasm it only
accounts for 4% of all chronic lymphoproliferative disorders.
Normally activated cytotoxic T-cells are eliminated through
Fas-mediated apoptosis. T-LGL cells however, are resistant to Fas-
mediated apoptosis [9,10]. Studies have shown that LGL leukemia
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TABLE I. Patient’s Clinical Data
Date WBC ANC HGB PLT RETIC Clinical features Therapy
February 1997 8.0 3360 12.4 119,000 IV IgG
July 1998 4.0 1120 10.3 99,000 Diffuse adenopathy 6-MP
December 1999 7.0 6.2 56,000 12.7 AIHA-Coombs’
positive
Prednisone
January 2001 3.4 7.1 94,000 AIHA continued CSAþ Prednisone
January 2002 3.2 2100 13.1 149,000 PDN
April 2002 7.9 6.4 17.9 AIHA Rituximabþ prednisone
May 2002 2.9 800 10.7 157,000 4.0 CSAþ Prednisone
November 2002 3.5 400 12.4 120,000
June 2003 4.3 344 10.1 79,000 AIHA Rituximab
September 2003 2.9 200 8.0 83,000 2.84 Massive splenomegaly
October 2003 2.0 300 7.5 86,000 4.34 6-MP, then splenectomy
November 2003 6.6 10.2 144,000
December 2003 10.6 4020 11.3 501,000 January!massive
ascites
December 2004 23.8 500 11.5 443,000




March 2005 18.4 2945 9.2 356,000 Weekly MTX
November 2005 11.6 1500 11.4 382,000 Negative Coombs’ test Weekly MTX
December 2005 10.7 2600 13.1 405,000 0.86 Weekly MTX
Brief Reports 143
cells express high levels of Fas ligand and sera from patients with
LGL leukemia contain high levels of soluble Fas. Overall the
evidence suggests that at least some cases of LGL leukemia are
caused by dysregulation of apoptosis due to abnormalities in the
Fas/ Fas-ligand pathway.
LGL is commonly associated with various clinical disorders
including autoimmune disorders, hematological diseases and
malignancies. The most frequent association is with RA which
occurs in up to 1/3 or patients [3]. Autoimmune thrombocytopenia,
autoimmune hemolytic anemia and pure red cell aplasia have also
been seen. Felty described five patients with RA, leukopenia and
splenomegaly in 1924 and this triad is now known as Felty’s
syndrome (FS). Considerable clinical overlap has been observed
between the LGL and FS. Both have been characterized by
neutropenia, splenomegaly and arthritis. T-cells have also been
implicated in the joint destruction associated with RA and
approximately 1/3 of patients with FS have a clonal proliferation
of T-cells [12]. Some experts in the field are of the opinion that these
two disorders are on a continuum of a single disease process.
Initially the diagnostic criteria for LGL included an absolute large
granular lymphocytosis greater than 2.0 109/L. As the criteria for
diagnosing LGL has changed over the years more patients with FS
would now be classified as having LGL on the basis of flow
cytometry and molecular analysis for TCR gene rearrangement. FS
and LGL also share a common immunogenic link. Patients with
these disorders have a similar frequency of the HLA-DR4 allele
(80–90%) [13]. Interestingly patients with T-LGLwithout RA have
a 33% frequency of this allele that is similar to racially matched,
normal controls [14]. It appears that FS and T-LGL are related
disorders where the presence of clonal TCR gene rearrangements is
seen in T-LGL and not in patients with FS. Why some patients with
RA are prone to develop a clonal expansion of T-LGL has not been
elucidated. Our patient, like others with HIGM Syndrome, shares
the feature of having chronic autoimmune disease which may be
a harbinger of LGL. Others have linked the predisposition to
autoimmune disease and LGL to specific HLA subtypes [1].
The causes of neutropenia seen in FS and T-LGL can be reduced
to problems with production, distribution and destruction. Early
studies of neutropenia in patients with FS discovered two distinct
groups [15]. Evidence of humoral mediated neutrophil destruction
was seen in 60% of patients. These patients had either non-
complexed immunoglobulin (presumed to be anti-neutrophil anti-
bodies) and/or immune complexes. The other 40% of patients
lacked neutrophil-bound immunoglobulin but were reported to have
decreased granulocyte colony growth in bone marrow cultures. Cell
mediatedmechanisms have also been implicated in the pathogenesis
of neutropenia inT-LGL.The dysregulation of apoptosis via the Fas/
Fas-ligand pathway that is responsible for T-LGL cell survival is
also related to the development of neutropenia in these patients [16].
T-LGL cells constitutively express Fas-ligand on their cell surface.
The Fas-ligand receptor, Fas (CD95) is expressed on a variety of
cells including normal granulocytes. In fact neutrophils express
higher levels of Fas than eosinophils or monocytes. This would
make neutrophils more susceptible to apoptosis in the presence of
Fas-activating antibody [17]. Neutropenia may also result from
increased margination due to precipitated immune complex
activation of neutrophils [18]. Thus in any given patient with T-
LGL any or all of these mechanisms might be involved in the
pathogenesis of neutropenia.
While T-cell LGL is most often a chronic, indolent disease the
majority of patients will require therapy at some point. In rare cases
patients may go into a spontaneous remission. Indications to initiate
therapy include severe neutropenia (ANC< 500) or recurrent
infections in those with less severe neutropenia and symptomatic
or transfusion dependent anemia [1]. Therapeutic approaches have
included methotrexate at 10 mg/m2/week orally [19]. This regimen
leads to complete remission in approximately 75% of patients
though continued treatment is often required to sustain remission
and several months of treatment are usually needed before counts
improve. Cyclosporine A has also been used as an alternative to
methotrexate [20] and in a small study of 25 patients, 50% had a
response to therapy and 24% of patients achieved a complete
Pediatr Blood Cancer DOI 10.1002/pbc
TABLE II. Flow Cytometry on Peripheral Blood
Marker description % Positive
Patient References
CD2 T-cell/NK cell 98.6 (H) 69–85
CD3 T-cell 98.6 (H) 59–79
CD4 T-Helper/Inducer 2.8 (L) 36–52
CD5 T-cell/B subset 98.5 (H) 59–72
CD7 T-cell/NK Cell 97.3 (H) 62–84
CD8 T-suppressor/Cytotoxic 95.7 (H) 19–29
CD10 B-Cell/Gran 0.2 (L) 0.3–1.7
CD11c Mono/Gran/NK/T subset 79.1 (H) 3–15
CD14 Monocytes 0.0
CD16, 56 NK cell 0.3
CD19 B cell 0.9 (L) 3–13
CD20 B cell 1.9 6–12
CD22 B cell 1.4
CD23 B cell subset 0.1
FMC7 B cell subset 1.5
KAPPA Kappa light chain 0.5 4–16
LAMBDA Lambda light chain 0.4 2–12
H, high; L, low.
These finding show a markedly abnormal elevation of cytotoxic T-cell and reduced number of B cells.
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remission. Patients with T-LGL and myelodysplasia have a lower
response rate to cyclosporine than those with T-LGL alone.
Cyclophosphamide in combination with prednisone produces
responses at a higher rate than prednisone alone with overall
response rates of 66% and a median duration of 32 months. Growth
factors such as GM-CSF or G-CSF have been used to more rapidly
increase neutrophil counts in patients with severe neutropenia.
While T-LGL is very uncommon in children is should be
considered in the appropriate clinical setting of a patient with
chronic anemia, neutropenia and/or thrombocytopenia and
increased large granular lymphocytes on peripheral blood smear.
The diagnosis ismade by demonstrating expansion of a T-cell or NK
cell population on flow cytometry along with clonal TCR gene
rearrangement by molecular studies.
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Peripheral T-Cell Lymphoma in a Five Year Old
M.W. Beresford, PhD,* S. Wilkins, MBChB, M. Ashworth, MBChB, J.E. Davidson, MBChB,
H. McDowell, PhD, and A.G. Cleary, MBChB
INTRODUCTION
Determining the diagnosis of a persistently pyrexial child with
panniculitic rash and systemic upset requires extensive multi-
system investigation.
We report a case presenting with persistent pyrexia that led to the
diagnosis of peripheral T-cell lymphoma, a rare malignancy in
childhood. The case illustrates diagnostic conundrums in a patient
who is not responding as expected to treatment. Pediatr Blood
Cancer 2008;50:145–147.  2006 Wiley-Liss, Inc.
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